多发性硬化症患者与奥克立珠单抗相关的隐源性组织化肺炎：两份病例报告和全面的文献综述。

IF 4.8 2区医学 Q1 CLINICAL NEUROLOGY Multiple Sclerosis Journal Pub Date : 2024-11-21 DOI:10.1177/13524585241295677

Alessandro Gans, Elena Pinuccia Verrengia, Elisabetta Ricchiuti, Serena Leva, Simona Brajkovic, Daniele Colombo, Antonino Mazzone, Alessandro Prelle

{"title":"多发性硬化症患者与奥克立珠单抗相关的隐源性组织化肺炎：两份病例报告和全面的文献综述。","authors":"Alessandro Gans, Elena Pinuccia Verrengia, Elisabetta Ricchiuti, Serena Leva, Simona Brajkovic, Daniele Colombo, Antonino Mazzone, Alessandro Prelle","doi":"10.1177/13524585241295677","DOIUrl":null,"url":null,"abstract":"Background: Cryptogenic organizing pneumonia (COP) is an interstitial lung disease, with causes including anti-CD20 antibodies. Ocrelizumab is a humanized monoclonal antibody against CD20 approved for use in relapsing-remitting or primary progressive multiple sclerosis (MS), with no conclusive data regarding pulmonary toxicity.Cases: We describe two cases of COP associated with ocrelizumab use in multiple sclerosis patients.Conclusions: We suggest considering COP whenever respiratory symptoms arise in MS patients receiving ocrelizumab therapy. COP diagnosis requires clinical and radiological exclusion of alternative diagnoses such as opportunistic infections, autoimmunity, drugs, and neoplasms. Appropriate steroid therapy has an excellent clinical response rate.","PeriodicalId":18874,"journal":{"name":"Multiple Sclerosis Journal","volume":" ","pages":"13524585241295677"},"PeriodicalIF":4.8000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review.\",\"authors\":\"Alessandro Gans, Elena Pinuccia Verrengia, Elisabetta Ricchiuti, Serena Leva, Simona Brajkovic, Daniele Colombo, Antonino Mazzone, Alessandro Prelle\",\"doi\":\"10.1177/13524585241295677\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Cryptogenic organizing pneumonia (COP) is an interstitial lung disease, with causes including anti-CD20 antibodies. Ocrelizumab is a humanized monoclonal antibody against CD20 approved for use in relapsing-remitting or primary progressive multiple sclerosis (MS), with no conclusive data regarding pulmonary toxicity.Cases: We describe two cases of COP associated with ocrelizumab use in multiple sclerosis patients.Conclusions: We suggest considering COP whenever respiratory symptoms arise in MS patients receiving ocrelizumab therapy. COP diagnosis requires clinical and radiological exclusion of alternative diagnoses such as opportunistic infections, autoimmunity, drugs, and neoplasms. Appropriate steroid therapy has an excellent clinical response rate.\",\"PeriodicalId\":18874,\"journal\":{\"name\":\"Multiple Sclerosis Journal\",\"volume\":\" \",\"pages\":\"13524585241295677\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Multiple Sclerosis Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/13524585241295677\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/13524585241295677","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：隐源性组织化肺炎（COP）是一种间质性肺病，病因包括抗CD20抗体。奥克立珠单抗是一种抗 CD20 的人源化单克隆抗体，已被批准用于治疗复发性缓解型或原发性进展型多发性硬化症（MS），目前尚无有关肺毒性的确凿数据：我们描述了两例与多发性硬化症患者使用奥克立珠单抗相关的 COP 病例：我们建议接受奥克立珠单抗治疗的多发性硬化症患者在出现呼吸道症状时考虑 COP。COP的诊断需要通过临床和放射学排除其他诊断，如机会性感染、自身免疫、药物和肿瘤。适当的类固醇治疗具有极佳的临床反应率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review.

Background: Cryptogenic organizing pneumonia (COP) is an interstitial lung disease, with causes including anti-CD20 antibodies. Ocrelizumab is a humanized monoclonal antibody against CD20 approved for use in relapsing-remitting or primary progressive multiple sclerosis (MS), with no conclusive data regarding pulmonary toxicity.

Cases: We describe two cases of COP associated with ocrelizumab use in multiple sclerosis patients.

Conclusions: We suggest considering COP whenever respiratory symptoms arise in MS patients receiving ocrelizumab therapy. COP diagnosis requires clinical and radiological exclusion of alternative diagnoses such as opportunistic infections, autoimmunity, drugs, and neoplasms. Appropriate steroid therapy has an excellent clinical response rate.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Multiple Sclerosis Journal 医学-临床神经学

CiteScore

10.90

自引率

6.90%

发文量

186

审稿时长

3-8 weeks

期刊介绍： Multiple Sclerosis Journal is a peer-reviewed international journal that focuses on all aspects of multiple sclerosis, neuromyelitis optica and other related autoimmune diseases of the central nervous system. The journal for your research in the following areas: * __Biologic basis:__ pathology, myelin biology, pathophysiology of the blood/brain barrier, axo-glial pathobiology, remyelination, virology and microbiome, immunology, proteomics * __Epidemology and genetics:__ genetics epigenetics, epidemiology * __Clinical and Neuroimaging:__ clinical neurology, biomarkers, neuroimaging and clinical outcome measures * __Therapeutics and rehabilitation:__ therapeutics, rehabilitation, psychology, neuroplasticity, neuroprotection, and systematic management Print ISSN: 1352-4585